1.
Med Oncol
; 28 Suppl 1: S246-9, 2011 Dec.
Article
in English
| MEDLINE
| ID: mdl-20936376
ABSTRACT
Sorafenib, a new antiangiogenic and antiproliferative agent, is currently used for hepatocellular and renal cell carcinoma. We report here the case of a patient with two cancers, a locally advanced cancer of the piriform sinus and a hepatocellular carcinoma, who was given sorafenib. Tumor response of both cancers might suggest that sorafenib could be effective against head and neck cancer.
Subject(s)
Benzenesulfonates/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Head and Neck Neoplasms/drug therapy , Liver Neoplasms/drug therapy , Portal Vein/pathology , Pyridines/therapeutic use , Venous Thrombosis/drug therapy , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/diagnosis , Head and Neck Neoplasms/complications , Head and Neck Neoplasms/diagnosis , Humans , Liver Neoplasms/complications , Liver Neoplasms/diagnosis , Male , Middle Aged , Neoplasm Metastasis/diagnosis , Neoplasm Metastasis/drug therapy , Niacinamide/analogs & derivatives , Phenylurea Compounds , Sorafenib , Treatment Outcome , Venous Thrombosis/complications , Venous Thrombosis/diagnosis
2.
Acta Oncol
; 49(8): 1390-1, 2010 Nov.
Article
in English
| MEDLINE
| ID: mdl-20825356